Richard Pzena
Pzena Investment Management
Richard Pzena United Therapeutics Corp stake
total: 584
Pzena Investment Management UTHR trades
- Total transactions:
- 16
- New positions:
- 3
- Sold out:
- 3
- Added:
- 5
- Reduced:
- 5
- Held since:
- 2023 Q1
- Held for:
- 6 quarters
- Latest activity:
- 2024 Q3
According to 2026 Q2 report, Richard Pzena doesn't hold any United Therapeutics Corp (UTHR) shares. To date, the estimated cost basis is nearly $223.35 for "buy" trades and estimated average "sell" price is $310.08. Pzena Investment Management first purchased UTHR in 2020 Q2, initially acquiring 5,278 shares. Richard Pzena later completely sold out the position and invested in United Therapeutics Corp again in 2023 Q1. Since the initial investment in United Therapeutics Corp (UTHR), Pzena Investment Management has made 15 more transactions.
When did Richard Pzena sell United Therapeutics Corp (UTHR)?
Richard Pzena sold off the entire United Therapeutics Corp (UTHR) position in 2024 Q3.
When did Richard Pzena buy United Therapeutics Corp (UTHR)?
Richard Pzena first invested in United Therapeutics Corp (UTHR) in 2020 Q2 at the reported quarter-end price of $121.07 per share.
What's the cost basis of Pzena Investment Management's UTHR stake?
The estimated cost basis for United Therapeutics Corp (UTHR) stake is around $223.35 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $223.35
- Weighted AVG sell price:
- $310.08
Richard Pzena's historical trades in United Therapeutics Corp
16 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2024 Q3
|
0.00%
|
0
|
$318.55
|
|
-100% (-1,599)
|
-0%
|
|
2024 Q2
|
0.00%
|
1,599
|
$318.55
|
$509,361
|
-23.75% (-498)
|
-0%
|
|
2024 Q1
|
0.00%
|
2,097
|
$229.72
|
$481,723
|
+3.71% (+75)
|
+0%
|
|
2023 Q4
|
0.00%
|
2,022
|
$219.89
|
$444,618
|
+8.53% (+159)
|
+0%
|
|
2023 Q3
|
0.00%
|
1,863
|
$225.87
|
$420,796
|
-10.17% (-211)
|
-0%
|
|
2023 Q2
|
0.00%
|
2,074
|
$220.75
|
$457,836
|
+21.64% (+369)
|
+0%
|
|
2023 Q1
|
0.00%
|
1,705
|
$223.96
|
$381,852
|
new
|
+0%
|
|
2022 Q2
|
0.00%
|
0
|
$179.55
|
|
-100% (-2,768)
|
-0%
|
|
2022 Q1
|
0.00%
|
2,768
|
$179.55
|
$497,000
|
+7.00% (+181)
|
+0%
|
|
2021 Q4
|
0.00%
|
2,587
|
$216.08
|
$559,000
|
-7.47% (-209)
|
-0%
|
|
2021 Q3
|
0.00%
|
$184.55
|
+21.78% (+500)
|
|||
|
2021 Q2
|
0.00%
|
$179.44
|
new
|
|||
|
2021 Q1
|
0.00%
|
$151.78
|
-100% (-4,289)
|
|||
|
2020 Q4
|
0.00%
|
$151.78
|
-15.79% (-804)
|
|||
|
2020 Q3
|
0.00%
|
$100.92
|
-3.51% (-185)
|
|||
|
2020 Q2
|
0.00%
|
$121.07
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.